alexa Rapid Progress Of Next Generation Sequencing Technology: Implications For Implementation In Clinical Diagnostic Laboratories | 28244
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

World Congress on Pathology and Microbiology

Manila, Philippines
Share This Page

Rapid progress of next generation sequencing technology: Implications for implementation in clinical diagnostic laboratories

4th International Conference and Exhibition on Pathology

R Rajesh Singh

ScientificTracks Abstracts-Workshop: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.016

In the past few years, the massively parallel sequencing capabilities of NGS have found widespread acceptance for clinical genomics in molecular diagnostic laboratories. Due to rapid progress, the underlying technology and the associated informatics is constantly evolving resulting in considerable process improvements in relatively short durations. Although desirable, these constant upgrades pose a challenge for clinical sequencing assays being used for clinical purposes due to the need of through validation before implementation. Here, in the context of a CAP and CLIA accredited molecular diagnostic laboratory the advantages and challenges posed by the constant upgrades for routine NGS testing of solid tumors and hematological malignancies will be presented. The progress in the wet bench and informatics portions of major NGS platforms will be highlighted.
Rajesh Singh has a PhD in Biochemistry from The University of Mysore, India and Postdoctoral research experience from University of Texas, MD Anderson Cancer Center. He has extensive experience in cancer biology focusing on the deregulated oncogenic and tumor suppressor pathways in the origin and maintenance of solid tumors and hematological malignancies. He is an Assistant Professor and Director Clinical NGS Development in the molecular diagnostics laboratory at MD Anderson, where he supervises the design and validation of the NGS assays for routine mutational screening of tumors. He has published more than 40 papers and 3 review articles in reputed journals.